Company Profile

Immunovant, Inc is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
All Other Basic Organic Chemical Manufacturing (325199)

SIC:
Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
Immunovant, Inc.
Tom Dorney, MS, MBA
Investor Relations
info@immunovant.com

Company Contact
Immunovant, Inc.
320 W 37th Street
6th Floor
New York, NY 10018